scispace - formally typeset
Y

Yan Zhou

Researcher at Zhejiang University

Publications -  5
Citations -  1747

Yan Zhou is an academic researcher from Zhejiang University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 2 publications receiving 1085 citations.

Papers
More filters
Journal ArticleDOI

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.

TL;DR: Clinical manifestations such as fever, shortness of breath or dyspnea were associated with the progression of disease, and laboratory examination such as aspartate amino transferase(AST) > 40U/L, creatinine(Cr) ≥ 133mol/l, hypersensitive cardiac troponin I(hs-cTnI) > 28pg/mL, procalcitonin(PCT) > 0.5mg/L predicted the deterioration of disease.
Journal ArticleDOI

Pretreatment with Shenmai Injection Protects against Coronary Microvascular Dysfunction

TL;DR: Investigation of the effect of Shenmai injection on coronary microvascular dysfunction found that pretreatment with SMI could improve CMD by alleviating oxidative stress, inflammatory response, and apoptosis and then improving vascular endothelial function and microv vascular structure.
Journal ArticleDOI

Effect of Musk Tongxin Dropping Pill on Myocardial Remodeling and Microcirculation Dysfunction in Diabetic Cardiomyopathy

TL;DR: In this paper, the effect of Musk Tongxin Dropping Pill (MTDP) on myocardial remodeling and microcirculation dysfunction in diabetic cardiomyopathy (DCM) was explored.
Journal ArticleDOI

Fixed complex electrograms during sinus rhythm and local pacing: potential ablation targets for persistent atrial fibrillation

TL;DR: In this paper , local pacing was used to detect pathological complex electrograms during sinus rhythm (C-EGMs) in persistent atrial fibrillation patients and left-side accessory pathway (LAP) patients.
Journal ArticleDOI

P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis

TL;DR: Clopidogrel pretreatment was associated with significantly lower mortality, major adverse cardiovascular events, myocardial infarction and revascularization with no increase in major bleeding, however, these advantages were not observed with prasugrel or ticagrelor pretreatment.